

effectuate the 340B price on the covered entities' eligible covered outpatient drug purchases. Specific requirements detailing the type and frequency of such submittals will be defined in a **Federal Register** notice, to include claims level data elements for 340B-eligible dispenses. The data submitted by covered entities to manufacturers is comparable to data already being collected and maintained by covered entities through existing third-party vendor relationships.

Likely Respondents: Drug manufacturers and covered entities.

Burden Statement: Burden in the context of this information collection means the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems, if necessary, for the purpose of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review

the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below and were analyzed based on implementation of a potential Pilot compared to current data collection practices in the market.

The total annual burden hours estimated for this ICR reflect the number of respondents once an anticipated Pilot is implemented. This includes 11 manufacturers of IPAY 2026 and IPAY 2027 drugs.

Total Estimated Annualized Burden Hours:

TABLE 1

Form name	Number of respondents *	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
340B Program Rebate Model Pilot Program Plan Submission	11	1	11	8	88
Monthly purchase reports	11	12	132	2	264
Covered Entities reporting claims data to third party platform	** 15,249	52	792,948	5	3,964,740
Total	15,260		793,080		3,965,092

The 11 manufacturers will submit Plans and Monthly Purchase Reports (first two rows, above), while the 15,249 Covered Entities will submit Claims Data (third row, above). Therefore, the total number of respondents is 15,260

** As of April 1, 2026.

Amy P. McNulty,

Deputy Director, Executive Secretariat.

[FR Doc. 2026-11989 Filed 6-12-26; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Diabetes and Digestive and Kidney Diseases Advisory Council, July 01, 2026, 01:00 p.m. to July 01, 2026, 03:00 p.m., National Institutes of Health, Democracy II, National Institutes of Diabetes and Digestive and, 6707 Democracy Boulevard, Bethesda, MD 20892 which was published in the **Federal Register** published on March 19, 2026, FR Doc. 91 FR 13316.

This notice is being amended to add a one-hour open session from 1 p.m. to 2 p.m. The meeting is partially closed to the public.

Dated: June 10, 2026.

Margaret N. Vardanian,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-11936 Filed 6-12-26; 8:45 am]

BILLING CODE 4167-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, June 29, 2026, 10:00 a.m. to June 30, 2026, 06:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on June 01, 2026, 91 FR 32404, FR Doc No. 2026-10931.

The meeting is being amended to change the SRO/contact person from Konrad J. Krzewski to John Laity. The meeting is closed to the public.

Dated: June 11, 2026.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-11999 Filed 6-12-26; 8:45 am]

BILLING CODE 4167-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government Owned Inventions Available for License: Fluorophthalimides as Anti-Inflammatory Agents for Systemic and Neurodegenerative Disorders

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders.

FOR FURTHER INFORMATION CONTACT:

Inquiries related to this license opportunity should be directed to: Nikki Guyton, Ph.D., Unit Supervisor, NCI, Technology Transfer Center, Email: